See more : EVS Broadcast Equipment SA (EVSBY) Income Statement Analysis – Financial Results
Complete financial analysis of ChemoCentryx, Inc. (CCXI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ChemoCentryx, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Jia Group Holdings Limited (8519.HK) Income Statement Analysis – Financial Results
- Tubi Limited (TBUIF) Income Statement Analysis – Financial Results
- Pilot Energy Limited (PGY.AX) Income Statement Analysis – Financial Results
- Sanghi Industries Limited (SANGHIIND.BO) Income Statement Analysis – Financial Results
- Hitachi, Ltd. (HTHIF) Income Statement Analysis – Financial Results
ChemoCentryx, Inc. (CCXI)
About ChemoCentryx, Inc.
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 32.22M | 64.89M | 35.95M | 42.88M | 82.50M | 11.44M | 0.00 | 0.00 | 6.06M | 5.42M | 31.67M | 34.86M | 49.74M | 23.55M |
| Cost of Revenue | 302.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 31.92M | 64.89M | 35.95M | 42.88M | 82.50M | 11.44M | 0.00 | 0.00 | 6.06M | 5.42M | 31.67M | 34.86M | 49.74M | 23.55M |
| Gross Profit Ratio | 99.06% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 82.99M | 77.88M | 70.28M | 62.74M | 49.50M | 37.95M | 33.18M | 33.82M | 33.54M | 34.57M | 28.36M | 33.53M | 27.47M | 35.06M |
| General & Administrative | 0.00 | 42.19M | 24.16M | 20.41M | 16.51M | 14.71M | 14.51M | 13.58M | 11.63M | 10.48M | 7.62M | 7.29M | 6.58M | 9.16M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 78.85M | 42.19M | 24.16M | 20.41M | 16.51M | 14.71M | 14.51M | 13.58M | 11.63M | 10.48M | 7.62M | 7.29M | 6.58M | 9.16M |
| Other Expenses | 302.00K | 0.00 | -176.00K | 0.00 | 0.00 | -500.00K | 0.00 | 0.00 | 27.48M | 29.15M | 0.00 | 0.00 | 0.00 | -536.00K |
| Operating Expenses | 162.14M | 120.07M | 94.26M | 83.15M | 66.00M | 52.16M | 47.69M | 47.40M | 45.18M | 45.05M | 35.97M | 40.82M | 34.05M | 43.68M |
| Cost & Expenses | 162.45M | 120.07M | 94.26M | 83.15M | 66.00M | 52.16M | 47.69M | 47.40M | 45.18M | 45.05M | 35.97M | 40.82M | 34.05M | 43.68M |
| Interest Income | 859.00K | 2.46M | 4.96M | 3.53M | 1.37M | 757.00K | 384.00K | 494.00K | 501.00K | 533.00K | 402.00K | 436.00K | 297.00K | 1.76M |
| Interest Expense | -2.70M | 2.64M | 2.15M | 1.22M | 4.00K | 0.00 | 0.00 | 24.00K | 59.00K | 794.00K | 734.00K | 81.00K | 76.00K | 129.00K |
| Depreciation & Amortization | 3.14M | 797.00K | 1.64M | 512.00K | 418.00K | 348.00K | 477.00K | 543.00K | 576.00K | 592.00K | 754.00K | 660.00K | 713.00K | 707.00K |
| EBITDA | -131.31M | -51.92M | -51.70M | -36.23M | 18.28M | -39.62M | -46.83M | -46.36M | -38.04M | -38.51M | -3.13M | -2.43M | 16.71M | -17.66M |
| EBITDA Ratio | -407.49% | -80.00% | -143.80% | -84.50% | 22.16% | -346.44% | 0.00% | 0.00% | -627.69% | -710.56% | -9.88% | -6.96% | 33.58% | -74.97% |
| Operating Income | -134.45M | -55.18M | -58.30M | -40.27M | 16.49M | -40.72M | -47.69M | -47.40M | -39.12M | -39.63M | -4.30M | -5.96M | 15.70M | -20.13M |
| Operating Income Ratio | -417.24% | -85.03% | -162.17% | -93.92% | 19.99% | -356.10% | 0.00% | 0.00% | -645.46% | -731.32% | -13.58% | -17.09% | 31.55% | -85.46% |
| Total Other Income/Expenses | -1.84M | -179.00K | 2.81M | 2.30M | 1.37M | 757.00K | 384.00K | 470.00K | 442.00K | -261.00K | -316.00K | 2.79M | 221.00K | 1.63M |
| Income Before Tax | -131.76M | -55.36M | -55.49M | -37.97M | 17.86M | -39.96M | -47.31M | -46.93M | -38.67M | -39.89M | -4.62M | -3.17M | 15.92M | -18.49M |
| Income Before Tax Ratio | -408.87% | -85.31% | -154.34% | -88.55% | 21.65% | -349.48% | 0.00% | 0.00% | -638.17% | -736.13% | -14.58% | -9.09% | 32.00% | -78.52% |
| Income Tax Expense | -2.70M | 2.46M | 4.96M | 3.53M | 1.37M | 757.00K | 384.00K | 494.00K | 501.00K | 533.00K | 418.00K | -73.00K | 293.00K | -23.00K |
| Net Income | -129.06M | -55.36M | -55.49M | -37.97M | 17.86M | -39.96M | -47.31M | -46.93M | -38.67M | -39.89M | -4.62M | -3.10M | 15.62M | -18.47M |
| Net Income Ratio | -400.51% | -85.31% | -154.34% | -88.55% | 21.65% | -349.48% | 0.00% | 0.00% | -638.17% | -736.13% | -14.58% | -8.88% | 31.41% | -78.43% |
| EPS | -1.96 | -0.84 | -0.98 | -0.76 | 0.37 | -0.86 | -1.08 | -1.08 | -0.95 | -1.13 | -0.13 | -0.11 | 0.55 | -0.65 |
| EPS Diluted | -1.96 | -0.84 | -0.98 | -0.76 | 0.36 | -0.86 | -1.08 | -1.08 | -0.95 | -1.13 | -0.13 | -0.11 | 0.55 | -0.65 |
| Weighted Avg Shares Out | 65.69M | 65.69M | 56.90M | 49.81M | 48.41M | 46.43M | 43.89M | 43.28M | 40.92M | 35.41M | 35.25M | 28.21M | 28.47M | 28.21M |
| Weighted Avg Shares Out (Dil) | 65.69M | 65.69M | 56.90M | 49.81M | 49.62M | 46.43M | 43.89M | 43.28M | 40.92M | 35.41M | 35.25M | 28.21M | 28.47M | 28.21M |
ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis
Why ChemoCentryx Stock Tanked in 2021
3 Biotech Stocks That Could Double in 2022
ChemoCentryx's (CCXI) Stock Increases on Tavneos' FDA Nod
ChemoCentryx (CCXI) Gets Positive CHMP Opinion for Tavneos
Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)
ChemoCentryx (CCXI) Q3 Loss Narrower Than Expected, Sales Top
ChemoCentryx to Participate in Two Upcoming Investor Conferences
Big Pharma Is Going Holiday Shopping. Who's Next?
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports